Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment

Parkinsonism and Related Disorders

Volumn 3, Issue 2, 1997, Pages 103-107

  Ellis, Catherine ^a,c   Lemmens, Gilbert ^a   Parkes, J David ^a   Abbott, R J ^b   Pye, I F ^b   Leigh, P Nigel ^a   Ray Chaudhuri, K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Apomorphine; Neuropsychiatric; Parkinson's disease

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PSYCHOTROPIC AGENT; RISPERIDONE; SELEGILINE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSKINESIA; ERYTHEMA; FEMALE; HALLUCINATION; HUMAN; INJECTION SITE; MALE; MENTAL DISEASE; NAUSEA; NEUROPSYCHIATRY; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SKIN NODULE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031426297     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(97)00009-6     Document Type: Article

References (12)

1. Stibe CMH, Kempster PA, Lees AJ, Stern GM. Subcutaneous apomorphine in Parkinsonian on-off oscillations. Lancet 1988; i: 403-406.
2. Marsden CD, Parkes JD and Quinn N. Fluctuations of disabilities in Parkinson's disease - clinical aspects. In Movement Disorders, eds CD Marsden and S Fahn. Butterworths, London, 1982, pp. 96-122.
3. Corsini GU, Pitzalis GF, Bernardi F, Bocchetta A, Del Zompo M. The use of dopamine agonists in the treatment of schizophrenia. Neuropharmacology 1981; 20: 1309-1313.
4. Tamminga GA, Gotts MD, Thacker GK, Alphs LD, Foster NL. Dopamine agonist treatment of schizophrenic patients with n-propylnorapomorphine. Arch. Gen. Psych. 1986; 43 (4): 398-402.
5. Ray Chaudhuri K, Abbott RJ, Millac PAC. Subcutaneous apomorphine for Parkinsonian patients with psychiatric side effects on oral treatment. J. Neurol. Neurosurg. Psychiat. 1990; 54: 372-373.
6. Lees AJ. Dopamine agonists in Parkinson's disease; a look at apomorphine. Fundam. Clin. Pharmacol. 1993; 7: 121-128.
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol Neurosurg. Psychiat. 1992; 55: 181-184.
8. Fahn S and Elton R. Members of the UPDRS Development Committee Unified Parkinson's disease rating scale. In Recent Developments in Parkinson's Disease, eds S Fahn, CD Marsden, DM Calne and M Goldstein. Macmillan Healthcare Information, Florham Park, NJ, 1987, pp. 153-164.
9. Douglas CJ. Apomorphine as an hypnotic. NY Med. J. 1900; 71: 376-378.
10. Ruggieri S, Stocchi F, Carta A, Agnoli A. Side effects of subcutaneous apomorphine in Parkinson's disease. Lancet 1989; i: 566.
11. Martin WR, Eades CE, Thompson JA, Huppler RE. The effects of morphine and naloprine-like drugs in the non-dependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976; 157: 517-532.
12. Cook L, Tam WS, Rohrbach KW. DuP 734 [1-(Cyclopropylmethyl)-4-(2′(4″-Flurophenyl)-2′-Oxoethyl)- Piperidine HBr], a potential antipsychotic agent: preclinical behavioural effects. J. Pharm. Exp. Ther. 1992; 263 (3): 1159-1166.